The pharmaceutical sector saw a notable decline following President-elect Donald Trump’s announcement of Robert F. Kennedy Jr. as his choice to lead the Department of Health and Human Services (HHS). Kennedy is a well-known vaccine skeptic and has been critical of the pharmaceutical industry, prompting concerns among investors about potential shifts in health policy affecting...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
